Millions of lives are being lost to viral diseases each year, and there is a continuing need for new and better antiviral therapies.
Clear Creek Bio’s mission is to develop therapies that meet the global need for safe, effective, and easy-to-administer antivirals.
Clear Creek Bio is a clinical-stage biotech developing oral antivirals for pandemic preparedness. We are focused on host-targeting and direct-acting small molecule antiviral therapeutics targeting SARS-CoV-2 and other medically important viruses.
Translating new insights in viral mechanisms, targeting both host and viral pathways.
The Clear Creek Bio team has diverse pharmaceutical leadership experience, successfully driving antiviral discovery, development, and clinical trials. Our team has successfully advanced programs across multiple therapeutic indications resulting in more than 20 NDA approvals including 10 in antivirals.